Vaccines and Global Health: The Week in Review
01 October 2022 :: Issue 673
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
**Milestones, Perspectives**

Gavi: Amid challenges, signs of recovery in routine immunisation as countries administer record volumes of vaccines in 2021

29 September 2022

- Routine immunisation coverage fell for a second consecutive year in 2021 across 57 Gavi-supported countries, although preliminary data shows signs of improvement in early 2022.
- Despite the drop in coverage, the 57 countries reached 65 million children through routine immunisation and administered more than 2 billion COVID-19 vaccines, according to Gavi’s 2021 Annual Progress Report.
- From Gavi’s founding in 2000 to the end of 2021, over 981 million children were reached via routine programmes; excluding COVID-19, more than 1.4 billion vaccinations have been administered through campaigns and more than 16.2 million future deaths have been averted.

Geneva, 29 September 2022 – Routine childhood immunisation experienced another challenging year in 2021 across the 57 countries supported by Gavi, the Vaccine Alliance, as basic vaccine coverage fell 1 percentage point to 77%, according to Gavi’s 2021 Annual Progress Report, which is published today. However, preliminary data for the first five months of 2022 suggests health systems may be recovering from the strains placed on them by the pandemic.

With 65 million children in Gavi-supported countries immunised through routine systems in 2021, Gavi’s work managed to generate more than US$ 18.9 billion in economic benefits, according to the Report. Another highlight of 2021 was the record US$ 161 million in co-financing contributed by Gavi-supported countries, which indicates further progress towards sustainability and country commitment to protecting childhood immunisation.

The Report also considers the fact that, with Gavi countries also administering more than 2 billion COVID-19 vaccines, their respective health systems were able to protect more people than ever before in 2021.

One area of strategic focus for the Vaccine Alliance in 2022 and beyond highlighted in the report is the increase in the number of zero-dose children, infants who have not received the first dose of diphtheria, tetanus and pertussis-containing vaccine (DTP1), which grew by 570,000 to 12.5 million – leaving them vulnerable to some of the world’s deadliest diseases, and making Gavi’s 5.0 mission to locate and reach them even more pressing.

Preliminary data from WHO suggests that countries’ immunisation programmes may be starting to recover. Among the 16 countries having reported data for January–May 2022, the data suggests a 2% increase. Gavi and its Alliance partners will be studying this data keenly in the coming months, to understand how countries are restoring their immunisation systems.
"We have faced significant challenges," said Prof José Manuel Barroso, Chair of the Gavi Board. "Routine immunisation continued to suffer in many countries in 2021 as a result of the pandemic. However, we are encouraged that the countries Gavi supports administered a record number of vaccine doses, both through routine programmes and also in their fight against COVID-19. Many countries did already begin to recover, which is a testament to heroic efforts made by their health systems and workers. As we move forward, we must maintain our focus on supporting routine immunisation and reaching zero-dose children with life-saving vaccines."

"Since 2019, we have seen the biggest sustained drop in routine immunisation in a generation, and millions of children are still missing out," said UNICEF Executive Director Catherine Russell. "Immunisation is one of the world’s most effective and cost-effective public health interventions. Working alongside Gavi and other key partners, we need to catch-up on missed children – especially ‘zero-dose’ children who have yet to receive a single immunisation against killer childhood diseases – and make sure lost ground does not become lost lives."

"One of the great ironies of the COVID-19 pandemic is that while it has spurred the largest vaccination campaign in history, it has also disrupted routine immunisation for many vaccine-preventable diseases,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Together with Gavi and other COVAX partners, WHO is committed to delivering vaccines against COVID-19 to end the pandemic, while scaling up routine immunisation services to reach every last child with life-saving vaccines.”
Bill & Melinda Gates Foundation Announces New Commitments for Vaccine Candidates With the Potential to Reduce Newborn and Infant Deaths in Lower-Income Countries

SEATTLE, September 28, 2022 – Today, the Bill & Melinda Gates Foundation announced grants totaling nearly US$128 million to support the development and accessibility of maternal vaccines for Group B Streptococcus (GBS) and Respiratory Syncytial Virus (RSV), two of the leading causes of death for newborns and young infants in lower-income countries.

No vaccines currently exist for these infections and treatment is too often out of reach in lower-income settings. These vaccines are being developed by Pfizer and, if successful and approved, would represent a significant advancement in the maternal immunization space. The GBS vaccine candidate could also be the first vaccine developed with a primary purpose for use during pregnancy to prevent infections in newborns and young infants. The foundation grants will fund work to help ensure the vaccines are accessible to pregnant women living in lower-income countries...

“Maternal immunization—vaccinating pregnant women who can then pass on lifesaving protection to their babies—is a powerful way to reduce newborn and infant mortality,” said Keith Klugman, director, pneumonia at the Bill & Melinda Gates Foundation. “However, for decades, innovation in this area has been underprioritized and underfunded, putting babies unnecessarily at risk for preventable infections. We are hopeful our investments in this promising pipeline of new maternal vaccines, including these two grants, will help infants in low-income settings have the best chance at life.”...

“If successful and approved or licensed, Pfizer’s vaccine candidates against GBS and RSV could have a profound impact on the health of young infants at a time when they are most vulnerable against these potentially devastating infections, particularly in lower-income countries where prevalence is higher,” said Annaliesa Anderson, Ph.D., senior vice president and chief scientific officer, vaccine research and development, Pfizer. “As part of Pfizer’s Accord for a Healthier World program focused on establishing access to our medicines and vaccines on a not-for-profit basis, the support for the vaccine candidates from the Gates Foundation will enable faster and more equitable deployment of the vaccines to these regions.”...

A $100 million grant will support the manufacturing of Pfizer’s GBS vaccine for Phase 3 clinical trials and, if successful, World Health Organization prequalification. It will also help fund the development of an affordable multidose vial for delivery of the vaccine in lower-income countries via public-sector purchasers, including Gavi, the Vaccine Alliance. This grant builds on a previous foundation investment for $17 million to help support Pfizer’s Phase 1/2 clinical trials that are exploring if protective antibodies could be transferred from immunized mothers to their babies.

A $27.5 million grant to Pfizer will support the development of an affordable multidose vial for delivery of the RSV vaccine candidate in lower-income countries via public sector purchasers, including Gavi. The work is co-funded by Pfizer and will include feasibility studies, clinical trial material manufacturing, and a trial to confirm that the multidose vial packaging designed for use in lower-income countries is comparable with what is used in high-income country markets.
Both grants are anchored in the principles of the Gates Foundation’s Global Access Policy, which ensures that knowledge generated from these efforts can be promptly and broadly disseminated and any resulting products be made available and accessible at an affordable price to the world’s poorest.

The Gates Foundation has committed nearly $540 million to maternal immunization efforts over the last 15 years, with an approach that focuses on evidence generation, product development and implementation. In addition to funding research and development for GBS and RSV, the foundation has supported the advancement of other maternal vaccines to prevent influenza, whooping cough and newborn bloodstream infections caused by bacteria other than GBS. Through foundation support and the collaboration of partners and grantees around the world, there’s hope that more women and their babies in lower-income countries will have access to lifesaving tools that can protect against key vaccine-preventable diseases.

::::

::::

**Featured Journal Content**

**Gates Open Research**
https://gatesopenresearch.org/browse/articles

*Selected Research*

*Research Article* metrics
Revised

**Modeling anticipated changes in numbers of SARS-CoV-2 infections within communities due to immunization campaigns** [version 2; peer review: 2 approved with reservations]
Kurt Frey, Brittany Hagedorn, Kevin A. McCarthy, Raymond Hutubessy, Susan Annemarie Wang
Peer Reviewers Sabina Marchetti; Sylvia K. Ofori
Funder
Global Good Fund
LATEST VERSION PUBLISHED 27 Sep 2022

**Abstract**

**Background:** As SARS-CoV-2 spread in early 2020, uncertainty about the scope, duration, and impact of the unfolding outbreaks caused numerous countries to interrupt many routine activities, including health services. Because immunization is an essential health service, modeling changes in SARS-CoV-2 infections among communities and health workers due to different vaccination activities was undertaken to understand the risks and to inform approaches to resume services.

**Methods:** Agent-based modeling examined the impact of Supplemental Immunization Activities (SIAs) delivery strategies on SARS-CoV-2 transmission in communities and health workers for six countries capturing various demographic profiles and health system performance: Angola, Ecuador, Lao PDR, Nepal, Pakistan, and Ukraine.

**Results:** Urban, fixed-post SIAs during periods of high SARS-CoV-2 prevalence increased infections within the community by around 28 [range:0-79] per 1000 vaccinations. House-to-house SIAs in mixed urban and rural contexts may import infections into previously naïve communities. Infections are elevated by around 60 [range:0-230] per 1000 vaccinations, but outcomes are sensitive to prevalence in health workers and SIA timing relative to peak.

**Conclusions:** Incremental increases in SARS-CoV-2 infection due to SIAs was small and in proportion to overall prevalence. Younger populations experience lower transmission intensity and fewer excess
infections per childhood vaccine delivered. Large rural populations have lower transmission intensity but face a greater risk of introduction of SARS-CoV-2 during an SIA.

---

**PHEIC**

**Monkeypox**

Public Health Emergency of International Concern (PHEIC)

https://www.who.int/emergencies/situations/monkeypox-oubreak-2022

No update on data table below:

Figure 1. Epidemiological curve of weekly aggregated confirmed cases of monkeypox by region, from 1 January to 17 September 2022 17:00 CEST*.

---

**PHEIC**

**Coronavirus [COVID-19] - WHO**

Public Health Emergency of International Concern (PHEIC)

https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Weekly Epidemiological and Operational updates

Last update: 30 Sep 2022

**Confirmed cases**: 614 385 693

**Confirmed deaths**: 6 522 600

**Vaccine doses administered**: 12 659 951 094

---
Weekly epidemiological update on COVID-19 – 28 September 2022

Overview

Globally, the number of new weekly cases decreased by 11% during the week of 19 to 25 September 2022, as compared to the previous week, with over three million new cases reported. The number of new weekly deaths decreased by 18%, as compared to the previous week, with just over 8900 fatalities reported.

As of 25 September 2022, 612 million confirmed cases and 6.5 million deaths have been reported globally.

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 25 September 2022**

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 07 July 2022

[New additions; Full scale view available at title link above]

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 01 Oct 2022

An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]
Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 01 Oct 2022]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability

COVID-19 Global Targets and Progress Tracker - IMF
The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

Duke – Launch and Scale Speedometer
**The Race for Global COVID-19 Vaccine Equity**

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research
COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out
01 Oct 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 120M total confirmed cases; 2.3M total confirmed deaths
Global vaccines administered: 12.7B
Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 350M
Other Delivered (Number of Doses): 390M
Total Delivered (Number of Doses): 740M
Total Administered (Number of Doses): 500M

Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/

https://data.covid19taskforce.com/data
A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.
The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed 01 Oct 2022: https://data.covid19taskforce.com/data. The global view below is complemented by country-specific dashboards here.

Our World in Data
:: 68% of the world population has received at least one dose of a COVID-19 vaccine.
:: 12.74 billion doses have been administered globally, and 3.58 million are now administered each day.
:: 22.7% of people in low-income countries have received at least one dose.

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

HHS
News
September 28, 2022 | News Release

FDA
Press Announcements
September 27, 2022 - Coronavirus (COVID-19) Update: FDA Updates COVID-19 Test Policy, Encourages Developers to Seek Traditional Premarket Review for Most Test Types
Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency
News & Press Releases
No new digest content identified.

******

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
Latest Updates [Selected]
News
Weekly COVID-19 country overview
Epidemiological update - 30 Sep 2022

News
Spread of hepatitis A virus strains of genotype IB in several EU countries and the United Kingdom
News - 29 Sep 2022

News
Joint ECDC-WHO/Europe monkeypox surveillance bulletin
Epidemiological update - 28 Sep 2022

News
Monkeypox situation update, as of 27 September 2022
Epidemiological update - 28 Sep 2022

******

European Commission
https://ec.europa.eu/commission/presscorner/home/en
Latest [Selected]
Press release 29 September 2022
Human rights: EU increases support to the protection of human rights defenders worldwide
Human rights are increasingly under threat worldwide.

Press release 28 September 2022
Commission launches call for displaced researchers from Ukraine
Today, the MSCA4Ukraine scheme, funded by the Commission under the Marie Skłodowska-Curie Actions, has published its call for applications to support displaced researchers from Ukraine.

Press release 26 September 2022
Monkeypox: Commission purchases treatment courses to meet immediate needs
Today, the Commission has secured over 10,000 treatment courses of tecovirimat to treat Monkeypox.
Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified.

Vaccine
Volume 40, Issue 39 Pages 5651-5748 (16 September 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/39
Research article Full text access

Determinants of COVID-19 vaccine hesitancy and resistance in Russia
Yana Roshchina, Sergey Roshchin, Ksenia Rozhkova
Pages 5739-5747
Abstract
Vaccination is the main tool available to handle the COVID-19 pandemic globally. Though no vaccine is proven to be 100% effective, vaccination secures against getting seriously ill and dying from the disease. Russia announced the development of its first domestic vaccine back in August 2020 and launched the nationwide immunization campaign at the beginning of 2021. Despite these achievements, as of mid-October 2021, only 36% of the population got at least one shot of the vaccine. Massive vaccination hesitancy and refusal pose a great threat to public health and postpone social and economic recovery. Using nationally representative data from the general adult population of Russia, this study explores the scope of vaccination hesitancy and refusal as well as the determinants
of vaccination attitudes. The results suggest that only 45% of the Russian population demonstrated positive attitudes towards the COVID-19 vaccination prior to the launch of a nationwide vaccination program. We analyze a wide array of demographic, socio-economic, and health-related factors in relation to vaccination intentions and explore the deep-rooted causes of vaccination reluctance by looking at personality traits, religiosity, and trust. The obtained results are vital for designing policy measures to promote vaccination.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

<table>
<thead>
<tr>
<th>Active (0.09%)</th>
<th>Discharged (98.73%)</th>
<th>Deaths (1.19%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>38293</td>
<td>44024164</td>
<td>528655</td>
</tr>
</tbody>
</table>

Total Vaccination: 2,18,68,45,847 (16,29,137 ↑)

Government of India – Press Information Bureau
Latest Press Releases
No new digest content identified.

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify any substantive, official announcements about China’s COVID response in general, or in Shanghai, Beijing or other China locations.]

PHEIC
Polio
Polio this week as of 28 Sep 2022 - GPEI
:: The 2022 Global Citizen Festival took place in New York last Saturday. During the event, Rotary President Jen Jones announced Rotary’s commitment of US $150M to the GPEI in support of the 2022-2026 Strategy. Malta also announced its pledge of €30,000 making these two the first major funding announcements before the pledging moment in October.
:: Pakistan is one of just two countries where the polio virus remains endemic. Challenges remain in identifying and vaccinating all children, but data management software is providing a way forward. Read more...

Summary of new polioviruses this week:
– Afghanistan: one WPV1 positive environmental sample
– Pakistan: four positive environmental samples
– Algeria: five cVDPV2 positive environmental samples
– DR Congo: nine cVDPV2 cases
– Egypt: one cVDPV2 positive environmental sample
– Mozambique : one cVDPV1 case
– Nigeria : six cVDPV2 positive environmental sample
– Yemen: 12 cVDPV2 cases

::::::
::::::

Editor’s Note:
See Journal Watch for the full text of this editorial:
The Lancet
Oct 01, 2022  Volume 400  Number 10358  p1079-1170
https://www.thelancet.com/journals/lancet/issue/current

Editorial
Polio eradication: falling at the final hurdle?
The Lancet
The past 3 years have seen remarkable developments in the effort to eradicate polio. In 2019, global eradication of type 3 poliovirus was declared. In 2020, Africa was classified as free from endemic polio. Wild poliovirus was confined to pockets of Afghanistan and Pakistan. But optimism is receding. Polio has returned to many parts of the world, and the upcoming replenishment to fund the eradication initiative comes amid geopolitical crises and global economic difficulties. The final stages of eradication have long been stuttering. Will 2022 be the year it finally slips away?...

::::::
::::::

UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
No new digest content identified.

Northern Ethiopia
No new digest content identified.
**Somalia**
No new digest content identified.

**Ukraine**
No new digest content identified.

::::::

**WHO & Regional Offices** [to 01 Oct 2022]
https://www.who.int/news
Selected News/Announcements/Statements
30 September 2022
Departmental news
**WHO announces updates to its guidelines on tests for the diagnosis of TB infection**

29 September 2022
Departmental news
**WHO launches new initiative to stop the spread of invasive malaria vector in Africa**

28 September 2022
Departmental news
**WHO/NTD reaffirms its commitment to Zero by 30 on World Rabies Day**

27 September 2022
Statement
**Joint statement of the United States of America and the World Health Organization on the U.S.-WHO strategic dialogue**

26 September 2022
Departmental news
**The WHO global infodemic manager community of practice is growing and tackling COVID-19, monkeypox and other outbreaks**

26 September 2022
Departmental news
**WHO releases a public health taxonomy for social listening on monkeypox conversations**

::::::

**WHO Director General Speeches** [selected]
https://www.who.int/director-general/speeches
Selected Speeches
30 September 2022  **Speech**
**WHO Director-General's opening remarks at the Global Preparedness Monitoring Board (GPMB) Board Meeting Hosted/organised by: GPMB Secretariat - 30 September 2022**

26 September 2022  **Speech**
WHO Director-General’s congratulatory remarks at the election of the Regional Director for the Americas, 74th Session of the WHO Regional Committee for the Americas—26 September 2022

26 September 2022  Remarks

Director-General’s opening remarks at the 30th Pan American Sanitary Conference – 26 September 2022

D:

WHO Regional Offices
Selected Press Releases, Announcements

WHO African Region
:: 27 September 2022
Democratic Republic of the Congo Ebola outbreak declared over, Uganda boosts response
:: 26 September 2022
Curbing Ebola resurgence risk among survivors in Democratic Republic of the Congo

WHO Region of the Americas PAHO
:: 30 Sep 2022

30th Pan American Sanitary Conference ends with regional agreements to improve pandemic preparedness and recover progress towards SDGs
Washington D.C., 30 September 2022 (PAHO/WHO) – The Pan American Health Organization’s (PAHO) 30th Pan American Sanitary Conference ended today following a week of discussions by ministers of health and other delegates on health priorities in the region. The conference approved thirteen resolutions, including a commitment to recover equitable...
:: 30 Sep 2022

PAHO calls on countries to continue COVID-19 testing and increase vaccination to avoid a prolonged pandemic
Washington, DC, 30 de September de 2022 (PAHO) - In an update on COVID-19 presented at the 30th Pan American Sanitary Conference, the Director of Health Emergencies of the Pan American Health Organization (PAHO), Ciro Ugarte, stated that “we are transitioning from an acute phase of the pandemic to more sustained control of the virus.” Since the...
:: 29 Sep 2022

Health authorities commit to step up efforts to keep the Americas free of polio
Washington, D.C., September 29 (PAHO) – Following declining levels of polio vaccination and surveillance across the region, and the recent confirmation of circulation of the poliovirus in the state of New York, health authorities in the Americas passed a resolution today to prioritize polio mitigation plans, including actions to increase...
:: 29 Sep 2022

Countries approve policy to strengthen regulatory systems for medicines and other health technologies in the Americas
Washington D.C. 29 September 2022 (PAHO/WHO) – Ministers of health throughout the Americas have endorsed a series of actions to strengthen national regulatory systems in all Member States, in order to ensure that medicines and health technologies are safe, effective and of quality, and are tailored to the needs of national health systems. The...
**Countries of the Americas Agree to Increase Genomic Sequencing to Detect Potentially Pandemic Pathogens**

Washington, DC, 28 September 2022 (PAHO) - Health authorities of the Region of the Americas agreed today to take a series of actions to expand and strengthen genomic surveillance of pathogens with pandemic and epidemic potential in the Region. The Strategy on Regional Genomic Surveillance for Epidemic and Pandemic Preparedness and Response,...

:: 28 Sep 2022

**Dr. Jarbas Barbosa da Silva Jr. of Brazil is Elected PAHO Director**

He will begin his five-year term on 1 February 2023 Washington, DC, 28 September, 2022 (PAHO/WHO) – Dr. Barbosa da Silva Jr., a national of Brazil, will be the new Director of the Pan American Health Organization (PAHO). He was elected today by PAHO Member States during the 30th Pan American Sanitary Conference. Dr. Barbosa da Silva Jr will...

:: 28 Sep 2022

**COVID-19 presents an opportunity to strengthen mental health in the Americas**

Washington, D.C. 28 September 2022 (PAHO/WHO) – The burden of mental health conditions has increased in the Americas due to COVID-19, and this situation has been exacerbated by social determinants of health such as poverty, high level health officials concluded during a side event at the 30th Pan American Sanitary Conference. “The COVID-19...

:: 27 Sep 2022

**Countries of the Americas Seek to Ensure Uninterrupted Care by Reducing Fragmentation of Health Systems**

Washington, DC, 27 September 2022 (PAHO) – Ministers of Health of the Region of the Americas agreed on a new policy to address the fragmentation of health systems, a problem that affects the organization, management, and delivery of care in almost the entire Region. The Policy on Integrated Care for Improved Health Outcomes was adopted by the...

:: 27 Sep 2022

**PAHO calls for more collaborative action to stop monkeypox outbreak in the region**

Member States, development partners and civil society key to stop spread and prevent monkeypox from gaining a foothold in the Region. Washington, D.C. 27 September (PAHO/WHO) – As monkeypox cases remain at around 40,000 in the Americas, the Pan American Health Organization (PAHO) today called on countries to intensify the response actions,...

**WHO South-East Asia Region SEARO**

No new digest content identified.

**WHO European Region EURO**

:: 28 September 2022  Joint News Release

**WHO and ILO call for new measures to tackle mental health issues at work**

27 September 2022  Statement

**Statement: The European Region is in a “permacrisis” that stretches well beyond the pandemic, climate change and war**

27 September 2022  News release

**Use of artificial intelligence on the rise, but its impact on health still limited, new study finds**

**WHO Western Pacific Region**

No new digest content identified.
Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

29 September 2022 | Ebola Virus Disease – Democratic Republic of the Congo
28 September 2022 | Marburg Virus Disease - Ghana
26 September 2022 | Ebola Disease caused by Sudan virus - Uganda

WHO Events
https://www.who.int/news-room/events/1
[Selected]
Strategic Advisory Group of Experts on Immunization (SAGE) - October 2022
3 – 6 October 2022

New WHO Publications
https://www.who.int/publications/i

Selected Titles
30 September 2022
WHO operational handbook on tuberculosis: module 3: diagnosis: tests for tuberculosis infection

30 September 2022
WHO consolidated guidelines on tuberculosis: module 3: diagnosis: tests for TB infection

28 September 2022
WHO Science Council meeting, Geneva, Switzerland, 11–12 July 2022: report

28 September 2022
WHO Ukraine crisis response: August 2022

27 September 2022
Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19

27 September 2022
Annexes to the interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19

25 September 2022
Ending the neglect to attain the sustainable development goals: a rationale for continued investment in tackling neglected tropical diseases 2021–2030
CDC/ACIP [U.S.] [to 01 Oct 2022]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases
No new digest content identified.

ACIP Meetings
Next ACIP Meeting
October 19-20

MMWR Weekly: Current Volume (71)
September 30, 2022 / No. 39
PDF of this issue
- Widespread Hepatitis A Outbreaks Associated with Person-to-Person Transmission — United States, 2016–2020
- Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents — 19 States, March 29–July 25, 2022
- Vital Signs: Use of Recommended Health Care Measures to Prevent Selected Complications of Sickle Cell Anemia in Children and Adolescents — Selected U.S. States, 2019

Coronavirus Disease 2019 (COVID-19)- CDC
Approximately 15 announcements/reports/data summaries.

Africa CDC [to 01 Oct 2022]
http://www.africacdc.org/
News
No new digest content identified.

China CDC
http://www.chinacdc.cn/en/
National Health Commission of the People's Republic of China [to 01 Oct 2022]
http://en.nhc.gov.cn/
News
Oct 1: Daily briefing on novel coronavirus cases in China
On Sept 30, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 172 new cases of confirmed infections

National Medical Products Administration – PRC [to 01 Oct 2022]
http://english.nmpa.gov.cn/
Chinese mainland reports 97 new local confirmed COVID-19 cases
2022-09-30
The Chinese mainland on Thursday reported 97 locally transmitted confirmed COVID-19 cases, the National Health Commission said Friday.

CCDC Weekly Reports: Current Volume (4)
2022-09-30 / No. 39 INTERNATIONAL DAY OF OLDER PERSONS ISSUE
View PDF of this issue
- Foreword: Building a Chronic Diseases Prevention and Rehabilitation System Throughout the Life Span to Proactively Respond to the Challenges of Accelerated Population Aging
- Preplanned Studies: Changes in Mortality Rates of Major Chronic Diseases Among Populations Aged Over 60 Years and Their Contributions to Life Expectancy Increase — China, 2005–2020
- Perspectives: Strengthening Systematic Research on Aging: Reflections from an Omics Perspective
- Commentary: Older European Adults and Access to Healthcare During the COVID-19 Pandemic

Organization Announcements
Editor’s Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group [to 01 Oct 2022]
https://alleninstitute.org/news-press/
News
No new digest content identified.

BMGF - Gates Foundation [to 01 Oct 2022]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
Press release Sep 28, 2022
Bill & Melinda Gates Foundation Announces New Commitments for Vaccine Candidates With the Potential to Reduce Newborn and Infant Deaths in Lower-Income Countries
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people.

News: Articles and Publications
No new digest content identified.

CARB-X  [to 01 Oct 2022]
https://carb-x.org/
News
No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation  [to 01 Oct 2022]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions of Vaccines and Global Health: The Week in Review are available here.
:: Informed Consent: A Monthly Review – September 2022 is now posted here
:: Genomic Medicine Governance, Ethics, Policy: A Quarterly Review - May 2022 is now posted here

CEPI – Coalition for Epidemic Preparedness Innovations  [to 01 Oct 2022]
http://cepi.net/
Latest News
No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES  [to 01 Oct 2022]
https://cioms.ch/
News; Publications
CIOMS Cumulative Glossary, with a focus on Pharmacovigilance (Version 2.0)
CIOMS 2022 :: 141 pages   SKU: 7912
The CIOMS Cumulative Glossary is an organized collection of the terms and definitions included in published CIOMS Working Group reports, with a focus on pharmacovigilance. It includes links to the reports and, where applicable, provides references to the sources from which the definitions were adopted or modified. Version 2.0 covers the terms included in twelve different CIOMS reports published between 1992 and 2022. It does not cover CIOMS reports on the subjects of ethics, clinical pharmacology, the Medical Dictionary for Regulatory Activities (MedDRA®), or publications resulting from CIOMS Roundtable Discussions (1967-1997).
DARPA – Defense Advanced Research Projects Agency [U.S.] [to 01 Oct 2022]
https://www.darpa.mil/news
News
No new digest content identified.

Duke Global Health Innovation Center [to 01 Oct 2022]
https://dukeghic.org/
Our Blog
No new digest content identified.

EDCTP [to 01 Oct 2022]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

Emory Vaccine Center [to 01 Oct 2022]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 01 Oct 2022]
http://www.euvaccine.eu/
Latest News, Events
No new digest content identified

Evidence Aid [to 01 Oct 2022]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
Selected Resources
No new digest content identified

Fondation Merieux [to 01 Oct 2022]
http://www.fondation-merieux.org/
News, Events
No new digest content identified
Amid challenges, signs of recovery in routine immunisation as countries administer record volumes of vaccines in 2021
29 September 2022
[See Milestones above for detail]
**Latest News**

No new digest content identified.

**ICRC** [to 001 Oct 2022]

*What’s New [Selected]*

**Mirjana Spoljaric Egger assumes the presidency of the International Committee of the Red Cross**

Geneva (ICRC) – Mirjana Spoljaric Egger assumed the presidency of the International Committee of the Red Cross (ICRC) on Saturday, 1 October, succeeding the outgoing president, Peter Maurer.

01-10-2022 | News release

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

*Selected Statements, Press Releases, Research*

No new digest content identified.

**IFFIm**
http://www.iffim.org/

*Press Releases/Announcements*

No new digest content identified.

**IFRC** [to 01 Oct 2022]

*Press Releases [Selected]*

No new digest content identified.

**Institut Pasteur** [to 01 Oct 2022]

*Press Documents*

No new digest content identified.

**IOM / International Organization for Migration** [to 01 Oct 2022]

*News*

No new digest content identified.

**ISC / International Science Council** [to 01 Oct 2022]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News, Blogs
No new digest content identified.

International Union of Immunological Societies (IUIS)
https://iuis.org/
News/Events [Selected]
16th International Symposium on Dendritic Cells 2022 (DC 2022)
Sunday 9th October 2022 at Pullman Cairns International

IVAC [to 01 Oct 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
Webinar: Achieving the Sustainable Development Goals – Reaching the Communities Left Furthest Behind
When: October 7th, 2022 at 8:30am-9:30am ET

IVI [to 01 Oct 2022]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.

Johns Hopkins Center for Health Security [to 01 Oct 2022]
https://www.centerforhealthsecurity.org/news/center-news/
Center News [Selected]
New Report Highlights Wide Variety of COVID-19 Response Activities Undertaken by Infectious Disease Experts Across US, Policies Needed to Strengthen Infectious Disease Workforce
September 30, 2022

MSF/Médecins Sans Frontières [to 01 Oct 2022]
http://www.msf.org/
Latest [Selected Announcements]
Ukraine
Over 200 psychiatric patients evacuated from overcrowded hospital in Kharkiv
Project Update 29 Sep 2022

Nigeria
UN must recognise ‘critical emergency’ malnutrition crisis in northwest Nigeria
Press Release 27 Sep 2022
Uganda

**Responding to the latest Ebola outbreak in Uganda**
Statement 26 Sep 2022

Democratic Republic of Congo

**Thousands affected by inter-communal violence in Maï-Ndombe province**
Project Update 26 Sep 2022

**National Academy of Medicine** - USA  [to 01 Oct 2022]
[https://nam.edu/programs/](https://nam.edu/programs/)

**News [Selected]**

**Joint Statement on Violence Against Health Care Workers**
September 30, 2022
AAMC (Association of American Medical Colleges) President and CEO David J. Skorton, MD, and National Academy of Medicine President Victor J. Dzau, MD, issued the following joint statement on violence […]

**National Academy of Sciences** - USA  [to 01 Oct 2022]

**News**

*No new digest content identified.*

**National Vaccine Program Office** - U.S. HHS  [to 01 Oct 2022]
[https://www.hhs.gov/vaccines/about/index.html](https://www.hhs.gov/vaccines/about/index.html)

**Upcoming Meetings/Latest Updates**

*No new digest content identified.*

**NIH**  [to 01 Oct 2022]

**News Releases**

**Study confirms link between COVID-19 vaccination and temporary increase in menstrual cycle length**
September 27, 2022 — Large NIH-funded study included participants in North America and Europe.

**NIH initiative to systematically investigate and establish function of every human gene**
September 27, 2022 — The Molecular Phenotypes of Null Alleles in Cells program will first look at protein-coding genes.

**PATH**  [to 01 Oct 2022]
[https://www.path.org/media-center/](https://www.path.org/media-center/)

**Press Releases**

*No new digest content identified.*
“Swasthya Sawari” a Mobile Van-Based Extension of Health & Wellness Centres Arrive at a Jharkhand District
The Rockefeller Foundation is collaborating on a new mobile health pilot program to reach underserved populations. Gumla, India | October 1, 2022 — In order to expand the reach and impact ...

Statement by Dr. Rajiv J. Shah, President of The Rockefeller Foundation, and Nancy Brown, CEO of the American Heart Association, on New Food Is Medicine Research Initiative
Good food is the foundation of good health. Unfortunately, for far too many Americans — especially Black, Latino/a, and Native Americans — affordable, nutritious food is out of reach. The ...

UNAIDS [to 01 Oct 2022]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
No new digest content identified.

UNHCR Office of the United Nations High Commissioner for Refugees [to 01 Oct 2022]
News Releases
Renewed as UN High Commissioner for Refugees, Grandi will keep striving for solutions
27 September 2022

UNICEF [to 01 Oct 2022]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
No new digest content identified.

Unitaid [to 01 Oct 2022]
https://unitaid.org/
Featured News
No new digest content identified.
Vaccine Equity Cooperative [nee Initiative] [to 01 Oct 2022]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 01 Oct 2022]
https://www.vaccineacceptance.org/
Announcements, Blog
No new digest content identified.

Vaccine Confidence Project [to 01 Oct 2022]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 01 Oct 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
News
Vaccine Update for Providers
September 2022
Announcements: Updated Q&As and schedule, archived webinar, & infographics

Wellcome Trust [to 01 Oct 2022]
https://wellcome.ac.uk/news
News. Opinion, Reports
No new digest content identified.

The Wistar Institute [to 01 Oct 2022]
Press Releases
No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 01 Oct 2022]
https://www.wfpha.org/
Latest News - Blog
Latest News
No new digest content identified.

World Bank [to 001 Oct 2022]
New Treatments Needed to Combat Rabies

28.09.2022

In a joint statement, the World Veterinary Association and the World Medical Association, say that dog-bite transmitted rabies is a disease of neglected populations, frequently in resource-poor areas. Most of these deaths would be avoidable if more than 70 per cent of dogs could be vaccinated and if bite victims would be properly treated through wound washing and timely post-exposure treatment. In short, the requisite tools to control rabies are currently available, however implementation of these tools is the current and greatest challenge.

Rabies control: a model for One Health collaboration

Published on 27 September 2022

As one of the deadliest zoonoses known to us, rabies still kills around 59,000 people every year, representing both a heavy public health and economic burden. Yet it is 100% preventable if we address the disease through a One Health approach.

Public Forum session highlights importance of youth engagement in trade and peacebuilding

30 September 2022

A Public Forum session on 30 September entitled “The Missing Peace” looked into how to involve youth in trade, policy-making and peacebuilding for a more sustainable future. In her opening remarks, Director-General Ngozi Okonjo-Iweala said: “I always say the WTO is about people — about making people’s lives better — and this has to include the young, wherever they happen to live because they are the future.”
ARM [Alliance for Regenerative Medicine] [to 01 Oct 2022]
Selected Press Releases
No new digest content identified.

BIO  [to 01 Oct 2022]
Press Releases
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network  [to 01 Oct 2022]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations  [to 01 Oct 2022]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA  [to 01 Oct 2022]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
Statements
IFPMA statement at the 74th session of the WHO Regional Committee for the Americas on
28 September 2022

IFPMA Statement at the WHO Second Public Hearings to support the intergovernmental
negotiating body to draft and negotiate a WHO convention, agreement or other
international instrument on pandemic prevention, preparedness and response
28 September 2022

International Alliance of Patients’ Organizations – IAPO  [to 01 Oct 2022]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
WHO-South Korea biomanufacturing training hub initiative (September 2022)

PhRMA  [to 01 Oct 2022]
http://www.phrma.org/
Press Releases
No new digest content identified.

:::
:::

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca
Press Releases - No new digest announcements identified

Bharat Biotech
Press Releases - No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias - No new digest announcements identified

Biological E
News - No new digest announcements identified

BioNTech
Press Releases
:: Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
28 Sep 2022
:: Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
26 Sep 2022

CanSinoBIO
News - Website not responding at inquiry

CIGB
Latest News - No new digest announcements identified

Cinnagen
Recent News - Website not responding at inquiry

Clover Biopharmaceuticals - China
News - No new digest announcements identified

Curevac [Bayer Ag – Germany]
**News** - No new digest announcements identified

**Gamaleya National Center**
*Latest News and Events* - See Russia above.

**GSK**
*Press releases for media* - No new digest announcements identified

**IMBCAMS**, China
*Home* - Website not responding at inquiry

**Janssen/JNJ**
*Press Releases* - No new digest announcements identified

**Medicago**
*Media* - No new digest announcements identified

**Merck**
*News releases* - No new digest announcements identified

**Moderna**
*Press Releases*
**European Medicines Agency Accepts Moderna’s Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine**
28 September, 2022

**Nanogen**
*News* - No new digest announcements identified

**Novartis**
*News* - No new digest announcements identified

**Novavax**
*Press Releases*
**Novavax Makes One Million Doses of Nuvaxovid™ Available for Use in the United Kingdom**
   GAITHERSBURG, Md., Sept. 27, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that an initial one million doses of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine are now available for use in the United Kingdom (U.K.). Nuvaxovid is the first protein-based COVID-19 vaccine granted authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) and will be offered per the Joint Committee on Vaccination and Immunisation (JCVI) advice.

**Pfizer**
*Recent Press Releases*
:: 09.28.2022  Updates and Statements
**Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age**
**Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age**

**Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVID-19**

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur
Press Releases - No new digest announcements identified

Serum Institute of India
NEWS & ANNOUNCEMENTS - No new digest announcements identified

Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPBIBP
News - No new digest announcements identified

Sinovac
Press Releases
SINOVAC-Sponsored Automated Complex for Vaccine Storage and Distribution is Delivered to the Egyptian
2022-09-24
On September 24, the handover ceremony of the Chinese government’s donation of COVID-19 vaccine to Egyptian women, children, and adolescents & the delivery ceremony of SINOVAC's sponsored automated complex for vaccine storage were held at VACSERA, the Egyptian biological products and vaccine company.

The 10 million doses of SINOVAC COVID-19 vaccine, CoronaVac, provided by the Chinese government through the organization of African First Ladies are the first batch of vaccines to be stored and transported after the cold storage is completed. These vaccines are specifically to help Egyptian women, children, and adolescents fight against the COVID-19 and strengthen the anti-epidemic capabilities of African women and children...

SK Biosciences
Press Releases - No new digest announcements identified

Valneva
Press Releases - No new digest announcements identified

Vector State Research Centre of Viralology and Biotechnology
Home - Website not responding [404 error]
**WestVac Biopharma**  
**Media** - No new digest announcements identified

**Zhifei Longcom**, China  
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]  
[No website identified]

---

**Journal Watch**

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. *Journal Watch* is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

---

**AJOB Empirical Bioethics**

Volume 13, 2022  Issue 3  
[Reviewed earlier]

**AMA Journal of Ethics**

Volume 24, Number 9: E817-912  Sep 2022  

*What We Owe Workers in Health Care Earning Low Wages*

If you're a professional caregiver in the US with colleagues paid a minimum wage, their labor is valued so little that it would be a crime to pay them less. The US Federal Fair Labor Standards Act of 1938 requires employers under its jurisdiction to pay workers at least a federal minimum wage. Yet in most of the US, a living wage is at least twice that amount. Privation, risk of injury and illness, uninsurance, and underinsurance undermine equity for health aides, environmental services workers, nursing and medical assistants, paramedics, and their children in the US. This theme issue investigates what we—as citizens, clinicians of status, and organizations—owe these vulnerable workers, on whose hour-to-hour care of some of our most vulnerable patients we heavily rely and woefully undervalue.

---

**American Journal of Infection Control**

October 2022  Volume 50  Issue 10  p1077-1192  
http://www.ajicjournal.org/current

Major Articles

*Optimized infection control practices augment the robust protective effect of vaccination for ESRD patients during a hemodialysis facility SARS-CoV-2 outbreak*
American Journal of Preventive Medicine
October 2022 Volume 63 Issue 4 p1118-1124

American Journal of Public Health
October 2022 112(10)

NOTES FROM THE FIELD
Integrated Multicultural Media Campaign to Increase COVID-19 Education and Vaccination Among Californians, 2021
Other Statistics/Evaluation/Research, Immunization/Vaccines, Other Race/Ethnicity, Statistics/Evaluation/Research, Health Promotion, Race/Ethnicity, Media
Martha Eugenia Dominguez, Dayanna Macias-Carlos, Jorge A. Montoya, Aaron Plant and Deborah Neffa-Creech
112(10), pp. 1389–1393

COVID-19 AND HEALTH EQUITY DATA GAPS
Disparate Impact of the COVID-19 Pandemic and Health Equity Data Gaps
Surveys, Surveillance, Statistics/Evaluation/Research
Denys T. Lau and Paulina Sosa
112(10), pp. 1404–1406

The Accumulation of Disadvantage: Black Children, Adolescents, and COVID-19 Data Inequity
Child and Adolescent Health, Other Race/Ethnicity, Socioeconomic Factors, Health Policy, Other Child and Adolescent Health, Race/Ethnicity, African Americans/Blacks
Vickie M. Mays, Susan D. Cochran, Jason L. Salemi and Elizabeth B. Pathak
112(10), pp. 1407–1411

Latinx Race and Ethnicity Data Gaps: The HACER Campaign and a Call to Action
Surveys, Surveillance, Statistics/Evaluation/Research, Public Health Practice, Health Administration
Diana Lemos, Paulina Sosa and Edward Vallejo
112(10), pp. 1412–1415

Data Equity in American Indian/Alaska Native Populations: Respecting Sovereign Nations’ Right to Meaningful and Usable COVID-19 Data
Other Statistics/Evaluation/Research, Immunization/Vaccines, Native Americans, Statistics/Evaluation/Research, Community Health, Health Policy, Race/Ethnicity
Vickie M. Mays, Abigail Echo-Hawk, Susan D. Cochran and Randall Akee
112(10), pp. 1416–1420
Trends in Collection of Disaggregated Asian American, Native Hawaiian, and Pacific Islander Data: Opportunities in Federal Health Surveys
Health Reform, Health Policy, Race/Ethnicity, Asians
Kevin H. Nguyen, Kaitlyn P. Lew and Amal N. Trivedi
112(10), pp. 1429–1435

LAW & ETHICS
Partisan Polarization of Childhood Vaccination Policies, 1995–2020
Immunization/Vaccines, Child and Adolescent Health, Community Health, Health Policy, Health Law, School Health
Kevin Estep, Annika Muse, Shannon Sweeney and Neal D. Goldstein

Conclusions. State lawmakers were more divided on vaccine policy, but partisan bills were less likely to pass. Bill characteristics associated with lower polarization could signal opportunities for future bipartisanship.

Public Health Implications. Increasing partisan polarization could alter state-level vaccine policies in ways that jeopardize childhood immunization rates or weaken responsiveness during public health emergencies. Authorities should look for areas of bipartisan agreement on how to maintain vaccination rates

American Journal of Tropical Medicine and Hygiene
Volume 107 (2022): Issue 3_Suppl (Sep 2022)
https://www.ajtmh.org/view/journals/tpmd/107/3_Suppl/tpmd.107.issue-3_Suppl.xml
Malaria Transmission Blocking Vaccines
[Reviewed earlier]

Annals of Internal Medicine
September 2022 Volume 175, Issue 9
http://annals.org/aim/issue
[Reviewed earlier]

Artificial Intelligence – An International Journal
Volume 310 September 2022
[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed 01 Oct 2022)
[No new digest content identified]

BMJ Global Health
August 2022 - Volume 7 - 8
https://gh.bmj.com/content/7/8
BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 01 Oct 2022)
[No new digest content identified]

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 01 Oct 2022)
Psychometric validation of a Chinese version of COVID-19 vaccine hesitancy scale: a cross-sectional study
COVID-19 vaccines have been administered in many countries; however, a sufficient vaccine coverage rate is not guaranteed due to vaccine hesitancy. To improve the uptake rate of COVID-19 vaccine, it is essenti...
Authors: Yiman Huang, Yijin Wu, Zhenwei Dai, Weijun Xiao, Hao Wang, Mingyu Si, Wenjun Wang, Xiaofen Gu, Li Ma, Li Li, Shaokai Zhang, Chunxia Yang, Yanqin Yu, Youlin Qiao and Xiaoyou Su
Citation: BMC Infectious Diseases 2022 22:765
Content type: Research Published on: 1 October 2022

Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany
Despite recommendations from the German Standing Committee on Vaccination (STIKO), pneumococcal vaccination coverage remains low in vulnerable populations. This study estimated the pneumococcal vaccination cov...
Authors: Arijita Deb, Bélène Podmore, Rosemarie Barnett, Dominik Beier, Wolfgang Galetzka, Nawab Qizilbash, Dennis Haeckl, Timo Boellinger, Kelly D. Johnson and Thomas Weiss
Citation: BMC Infectious Diseases 2022 22:753
Content type: Research Published on: 28 September 2022

Facilitators and barriers to COVID-19 vaccination among healthcare workers and the general population in Guinea
The advent of the effective COVID-19 vaccine was the most eagerly expected worldwide. However, this hope quickly became hesitation and denial in many countries, including Guinea. Understanding the reasons for ...
Authors: Almamy Amara Toure, Fodé Amara Traore, Gnooume Camara, Aboubacar Sidiki Magassouba, Ibrahima Barry, Mohamed Lamine Kourouma, Younoussa Sylla, Naby Yaya Conte, Diao Cisse, Nafissatou Dioubaté, Sidikiba Sidibe, Abdoul Habib Beavogui and Alexandre Delamou
Citation: BMC Infectious Diseases 2022 22:752
Content type: Research Published on: 27 September 2022

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 01 Oct 2022)
[No new digest content identified]
Transparency and reporting characteristics of COVID-19 randomized controlled trials

In the context of the COVID-19 pandemic, randomized controlled trials (RCTs) are essential to support clinical decision-making. We aimed (1) to assess and compare the reporting characteristics of RCTs between preprints and peer-reviewed publications and (2) to assess whether reporting improves after the peer review process for all preprints subsequently published in peer-reviewed journals. 

Conclusions

Transparency, completeness, and consistency of reporting of COVID-19 clinical trials were insufficient both in preprints and peer-reviewed publications. A comparison of paired reports published in preprint and peer-reviewed publication did not indicate major improvement.

Authors: Philipp Kapp, Laura Esmail, Lina Ghosn, Philippe Ravaud and Isabelle Boutron
Citation: BMC Medicine 2022 20:363
Content type: Research article Published on: 26 September 2022

The psychometric properties and the factorial structure of COVID-19 Vaccines Acceptance scale (VAC-COVID-19) within the Arabic language in a Palestinian context

Authors: Fayez Mahamid and Guido Veronese
Citation: BMC Public Health 2022 22:1833
Content type: Research Published on: 29 September 2022

Abstract

Background

The COVID-19 Vaccines Acceptance scale (VAC-COVID-19) is an international measure designed to evaluate vaccination acceptance against the COVID-19 virus. The current scale was translated from English to Arabic and validated within the Palestinian context.

Aims

Our study aimed to test the factorial structure and the psychotic properties of the VAC-COVID-19 within the Palestinian context using exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) through 484 participants selected using online method techniques.

Findings

The VAC-COVID-19 was a reliable and valid method in assessing COVID-19 vaccine acceptance among Palestinians. Results of CFA indicated a stable construct of a two-factor solution in assessing COVID-19 vaccination acceptance in a Palestinian context. (1) Reasons for not receiving the vaccination, and (2) for receiving the vaccination.

Conclusion
The VAC-COVID-19 was a valid method to assess vaccination acceptance in the Arabic language within the Palestinian context. Therefore, it is recommended to conduct similar studies with diverse samples in Palestinian society; it would be prudent to target at-risk populations needed to develop the scale and its factorial structure. The VAC-COVID-19 can be a useful measure to assess vaccination acceptance among Palestinians, enabling health providers to implement interventions to modify negative attitudes toward not receiving vaccinations.

Seasonal influenza vaccine uptake among healthcare workers in tertiary care hospitals, Bangladesh: Study protocol for influenza vaccine supply and awareness intervention
Healthcare workers (HCWs), such as doctors, nurses, and support staffs involved in direct or indirect patient care, are at increased risk of influenza virus infections due to occupational exposures.
Citation: BMC Public Health 2022 22:1819
Content type: Study protocol Published on: 24 September 2022

BMC Research Notes
http://www.biomedcentral.com/bmcresnotes/content
(Accessed 01 Oct 2022)
[No new digest content identified]

BMJ Evidence-Based Medicine
October 2022 - Volume 27 - 5
https://ebm.bmj.com/content/27/5
[Reviewed earlier]

BMJ Open
September 2022 - Volume 12 - 9
https://bmjopen.bmj.com/content/12/9
[Reviewed earlier]

Bulletin of the World Health Organization
Volume 100(9); 2022 Sep 1
https://www.ncbi.nlm.nih.gov/pmc/issues/415561/
[Reviewed earlier]

Cell
Sep 29, 2022 Volume 185 Issue 20 p3639-3838
https://www.cell.com/cell/current
[New issue; No digest content identified]
Clinical Pharmacology & Therapeutics
Volume 112, Issue 3  Pages: 413-729  September 2022
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current
[Reviewed earlier]

Clinical Therapeutics
July 2022  Volume 44  Issue 7  p927-1034
http://www.clinicaltherapeutics.com/current
[Reviewed earlier]

Clinical Trials
Volume 19 Issue 5, October 2022
https://journals.sagepub.com/toc/ctja/19/5
Articles
Open Access  Research article  First published 22 August, 2022  pp. 479–489
Analysis of adaptive platform trials using a network approach
Ian C Marschner
I Manjula Schou

Reviews
Open Access  Review article  First published 1 July, 2022  pp. 545–560
When is it impractical to ask informed consent? A systematic review
Sara JM Laurijssen
Rieke van der Graaf
Wouter B van Dijk
Ewoud Schuit
Rolf HH Groenwold[

Policy
Research article  First published 5 May, 2022  pp. 573–578
Risk-proportionate approach to paediatric clinical trials: The legal requirements, challenges, and the way forward under the European Union Clinical Trials Regulation
Mandy Wan
Elisa Alessandrini
Paul Brogan
Despina Eleftheriou
Adilia Warris[...]

Child Care, Health and Development
Volume 48, Issue 5  Pages: 659-879  September 2022
https://onlinelibrary.wiley.com/toc/13652214/current
[Reviewed earlier]
Conflict and Health
http://www.conflictandhealth.com/
[Accessed 01 Oct 2022]
[No new digest content identified]

Contemporary Clinical Trials
Volume 120  September 2022
https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/120/suppl/C
[Reviewed earlier]

The CRISPR Journal
Volume 5, Issue 4 / August 2022
https://www.liebertpub.com/toc/crispr/5/4
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 9, issue 4, December 2021
https://link.springer.com/journal/40142/volumes-and-issues/9-4
[Reviewed earlier]

Current Opinion in Infectious Diseases
October 2022 - Volume 35 - Issue 5
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1  December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 22, Issue 3  Pages: 123-180  September 2022
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 32, Issue 7, 2022
http://www.tandfonline.com/toc/cdip20/current
[New issue; No digest content identified]
Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 4 - August 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 46, Issue 4  Pages: 853-1126  October 2022
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

EMBO Reports
Volume 23  Issue 9  5 September 2022
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 28, Number 10—October 2022
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 40  September 2022
https://www.sciencedirect.com/journal/epidemics/vol/40/suppl/C
[Reviewed earlier]

Epidemiology and Infection
Volume 150 - 2022
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 44, Issue 5  Pages: 1-21  September–October 2022
https://onlinelibrary.wiley.com/toc/25782363/current
Protecting healthy volunteers • IRBs and research biopsies
[Reviewed earlier]

Ethics & International Affairs
Spring 2022 (36.1) | March 10, 2022
Ethics, Medicine and Public Health
Volume 23   August 2022
[Reviewed earlier]

The European Journal of Public Health
Volume 32, Issue 4, August 2022
https://academic.oup.com/eurpub/issue/32/4
[Reviewed earlier]

Expert Review of Vaccines
Vol 21 (9) 2022
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Foreign Affairs
Volume 101, Number 5   September/October 2022
https://www.foreignaffairs.com/issues/2022/101/5
[New issue; No relevant content identified]

Forum for Development Studies
Volume 49, 2022 - Issue 2
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

Genetics in Medicines
[Reviewed earlier]

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed  01 Oct 2022]
[No new digest content identified]

Global Health Action
Volume 15, Issue 1 (2022)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
Global Health: Science and Practice (GHSP)
August 2022 | Volume 10 | Number 4
http://www.ghspjournal.org/content/current
[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 01 Oct 2022]
[No new digest content identified]

Global Public Health
Volume 17, Issue 10 (2022)
http://www.tandfonline.com/toc/rgph20/current
(Re)imagining Research, Activism, and Rights at the Intersections of Sexuality, Health, and Social Justice
[Reviewed earlier]

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 01 Oct 2022]
[No new digest content identified]

Health and Human Rights
Volume 24, Issue 1, June 2022
[Reviewed earlier]

Health Economics, Policy and Law
Volume 17 - Issue 4 - October 2022
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 37, Issue 8, October 2022
https://academic.oup.com/heapol/issue/37/8
[Reviewed earlier]

Health Research Policy and Systems
Human Gene Therapy
Volume 33, Issue 17-18 / September 2022
https://www.liebertpub.com/toc/hum/33/17-18
[Reviewed earlier]

Humanitarian Practice Network
https://odihpn.org/
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 18, Issue 5, 2022
https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList
[Reviewed earlier]

Immunity
Sep 13, 2022 Volume 55 Issue 9 p1515-1750
https://www.cell.com/immunity/current Articles
[Reviewed earlier]

Infectious Agents and Cancer
http://www.infectagentscancer.com/
[Accessed 01 Oct 2022]
[No new digest content identified]

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 01 Oct 2022]
Empowering local research ethics review of antibacterial mass administration research
Authors: Nelson K. Sewankambo and Paul Kutyabami
Content type: Scoping Review 28 September 2022

International Health
Volume 14, Issue 5, September 2022
https://academic.oup.com/inthealth/issue/14/5
[Reviewed earlier]
**International Human Rights Law Review**
Volume 11 (2022): Issue 1 (Jun 2022)
https://brill.com/view/journals/hrlr/11/1/hrlr.11.issue-1.xml

**Table of Contents**
[Reviewed earlier]

**International Journal of Community Medicine and Public Health**
Vol 9, No 10 (2022) October 2022
https://www.ijcmph.com/index.php/ijcmph/issue/view/92

*Original Research Articles*

**The impact of COVID-19 pandemic response on uptake of routine immunizations and the assessment of a “catch-up” drive in the Gwalior district of Madhya Pradesh, India**
Ishant Kumar, Manish Chaturvedi, Deeksha Singh
Published: 2022-09-28

**International Journal of Epidemiology**
Volume 51, Issue 4, August 2022
https://academic.oup.com/ije/issue

[Reviewed earlier]

**International Journal of Human Rights in Healthcare**
Volume 15 Issue 2, 2022
https://www.emerald.com/insight/publication/issn/2056-4902/vol/15/iss/2

**Table of Contents**
[Reviewed earlier]

**JAMA**
September 27, 2022, Vol 328, No. 12, Pages 1161-1266
https://jamanetwork.com/journals/jama/currentissue

*Firearms and Violence*

**Original Investigation**

**Effect of High-Flow Nasal Cannula Oxygen vs Standard Oxygen Therapy on Mortality in Patients With Respiratory Failure Due to COVID-19 The SOHO-COVID Randomized Clinical Trial**
Jean-Pierre Frat, MD, PhD; Jean-Pierre Quenot, MD, PhD; Julio Badie, MD; et al.

This randomized clinical trial compares the efficacy of high-flow nasal cannula oxygen vs standard oxygen therapy in reducing the rate of mortality at day 28 in patients with respiratory failure due to COVID-19 admitted in intensive care units.

*Editorial*

**Respiratory Support in the Time of COVID-19**
Alistair D. Nichol, PhD; Cecilia O’Kane, PhD; Daniel F. McAuley, MD

**JAMA Pediatrics**  
September 2022, Vol 176, No. 9, Pages 837-952  
[https://jamanetwork.com/journals/jamapediatrics/currentissue](https://jamanetwork.com/journals/jamapediatrics/currentissue)  
[Reviewed earlier]

**JBI Evidence Synthesis**  
September 2022 - Volume 20 - Issue 9  
[https://journals.lww.com/jbisrir/Pages/currenttoc.aspx](https://journals.lww.com/jbisrir/Pages/currenttoc.aspx)  
[Reviewed earlier]

**Journal of Adolescent Health**  
September 2022, Volume 71, Issue 3, p251-380  
[https://www.jahonline.org/current](https://www.jahonline.org/current)  
[New issue; No digest content identified]

**Journal of Artificial Intelligence Research**  
Vol. 74 (2022)  
[https://www.jair.org/index.php/jair](https://www.jair.org/index.php/jair)  
[Reviewed earlier]

**Journal of Community Health**  
Volume 47, issue 5, October 2022  
[Reviewed earlier]

**Journal of Development Economics**  
Volume 158, September 2022  
[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**  
Volume 17 Issue 4, October 2022  
[http://journals.sagepub.com/toc/jre/current](http://journals.sagepub.com/toc/jre/current)  
[Reviewed earlier]

**Journal of Epidemiology & Community Health**  
September 2022 - Volume 76 - 9  
[https://jech.bmj.com/content/76/9](https://jech.bmj.com/content/76/9)
**Journal of Evidence-Based Medicine**

Volume 15, Issue 3  Pages: 181-314  September 2022  
https://onlinelibrary.wiley.com/toc/17565391/current

**EDITORIAL**

Risk factors, clinical manifestation, precaution, and management of monkeypox  
Dan Liu, Yuan Chi, Peige Song, Xiantao Zeng, Liang Du, Yaolong Chen, Sheyu Li  
Pages: 183-186  
First Published: 23 August 2022

**ARTICLES**

Clinical manifestations of COVID-19: An overview of 102 systematic reviews with evidence mapping  
Xufei Luo, Meng Lv, Xianzhuo Zhang, Janne Estill, Bo Yang, Ruobing Lei, Mengjuan Ren, Yunlan Liu, Ling Wang, Xiao Liu, Qi Wang, Min Meng, Yaolong Chen, the COVID-19 evidence and recommendations working group  
Pages: 201-215  
First Published: 31 July 2022

Efficacy and safety of COVID-19 vaccines: A network meta-analysis  
Ahmad A. Toubasi, Thuraya N. Al-Sayegh, Yazan Y. Obaid, Sarah M. Al-Harasis, Saif Aldeen S. AlRyalat  
Pages: 245-262  
First Published: 23 August 2022

**Journal of Global Ethics**

Volume 18, Issue 1, 2022  
http://www.tandfonline.com/toc/rjge20/current

**Special Issue: Relational Theory: Feminist Approaches, Implications, and Applications**  
Guest Editors Christine M. Koggel, Ami Harbin and Jennifer J. Llewellyn  
[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 33, Number 3, August 2022  
https://muse.jhu.edu/issue/48370

**Table of Contents**  
[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 24, issue 5, October 2022  

**Contents**  
[Reviewed earlier]
Journal of Immigrant & Refugee Studies  
Volume 20, 2022  _  Issue 3  
https://www.tandfonline.com/toc/wimm20/current  
[Reviewed earlier]

Journal of Infectious Diseases  
Volume 225, Issue 12, 15 June 2022  
https://academic.oup.com/jid/issue/225/12  
[Reviewed earlier]

Journal of International Development  
Volume 34, Issue 6  Pages: 1069-1255  August 2022  
https://onlinelibrary.wiley.com/toc/10991328/current  
[Reviewed earlier]

Journal of Medical Ethics  
September 2022  -  Volume 48  -  9  
http://jme.bmj.com/content/current  
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews  
Volume 9, Issue 3 (2022)  
https://institutionalrepository.aah.org/jpcrr/  
[Reviewed earlier]

Journal of Pediatrics  
September 2022  Volume 248  p1-136  
http://www.jpeds.com/current  
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice  
https://joppp.biomedcentral.com/  
[Accessed  01 Oct 2022]  
[No new digest content identified]

Journal of Public Health Management & Practice  
September/October 2022  -  Volume 28  -  Issue 5  
https://journals.lww.com/jphmp/pages/currenttoc.aspx  
[Reviewed earlier]
Editorial

Polio eradication: falling at the final hurdle?

The past 3 years have seen remarkable developments in the effort to eradicate polio. In 2019, global eradication of type 3 poliovirus was declared. In 2020, Africa was classified as free from endemic polio. Wild poliovirus was confined to pockets of Afghanistan and Pakistan. But optimism is receding. Polio has returned to many parts of the world, and the upcoming replenishment to fund the eradication initiative comes amid geopolitical crises and global economic difficulties. The final stages of eradication have long been stuttering. Will 2022 be the year it finally slips away?

The epidemiological situation is concerning. COVID-19 temporarily halted the Global Polio Eradication Initiative (GPEI)’s immunisation campaigns, putting over 80 million children at risk. Consequently, outbreaks of circulating vaccine-derived poliovirus (cVDPV) tripled from 2019 to 2020, with over 1100
children paralysed. Paralysis caused by wild poliovirus in Malawi in late 2021 marked a return of the virus to Africa. In 2022, cVDPVs have been detected in wastewater in the USA, UK, and Israel, although rapid vaccination campaigns should prevent them becoming an immediate threat to public health. Nigeria has faced a large outbreak of 415 cVDPV cases. PAHO has warned that Brazil, Dominican Republic, Haiti, and Peru are at high risk for reintroduction of polio, following dwindling vaccination rates. Global polio immunisation rates fell to 80% in 2021, the lowest rate in 14 years.

**GPEI's immediate concern is money. At a pledging event in October in Germany, it will ask for US$4·8 billion from partners and donor countries, and for political commitment to eradicate polio by 2026.** The strategy for 2022–26, if funded, will see the vaccination of 370 million children annually and continued surveillance for polio and other diseases in 50 countries. But will donors be willing? Among economic instability, cost-of-living crises, and concerns over fragmentation of global health financing, governments might not see polio as important. As outlined in a World Report, the Global Fund to Fight AIDS, Tuberculosis and Malaria failed to reach its recent fundraising target. Traditional global health entities are seemingly no longer the political priorities they once were.

In its latest report, the GPEI's Independent Monitoring Board has warned that any recent optimism “must be tempered by some cold realities”. Although there have been reductions in cases in Pakistan and Afghanistan, widespread flooding in Pakistan has put health-care delivery at risk. Vaccinations have restarted in Afghanistan, following the near breakdown of the entire health system after the Taliban's return to power; in February, eight vaccination workers were killed. The Board emphasises the need to engage with and secure commitments from local governments in wild poliovirus’ last strongholds.

**Novel polio vaccines should help control outbreaks of cVDPV and reduce the risk of new cases.** A novel oral polio type 2 vaccine, using a more genetically stable virus strain, has been given emergency authorisation by WHO. Data on its performance are being collected with the goal of full licensure, and potential use outside outbreak settings. But novel vaccines have been in short supply and technical solutions alone are not enough to overcome barriers to eradication.

In fact, the fundamental aims of the eradication programme have been questioned. Writing in The Lancet Global Health, Konstantin Chumakov and colleagues argued that GPEI should refocus on eradicating poliomyelitis as a disease, rather than eradicating the virus itself. Others have urged the programme to consider the eradication goal unobtainable and focus instead on sustained control of cases. Aidan O'Leary, Director for Polio Eradication at WHO, writes in The Lancet that, “While previous deadlines have come and gone, the Global Polio Eradication Initiative's 2022–2026 strategy has sharpened its approach to overcoming the remaining hurdles to eradication in the highest risk communities around the world”. **But it is reasonable to ask whether the dedication of huge amounts of money and effort to a vertical health programme for a single disease is fair.**

The GPEI has done indisputable good. Since its launch in 1988, it has overseen a 99·9% reduction in the global incidence of polio, saved more than 1·5 million lives, and spared an estimated 16 million people from paralysis. Two of the three serotypes of wild poliovirus (types 2 and 3) have been certified as eradicated worldwide. These are huge achievements. But the GPEI faces clear challenges that once again threaten the viability of the eradication programme. One thing is certain: a global resurgence of polio would be disastrous for health.
How Nature contributed to science’s discriminatory legacy

We want to acknowledge — and learn from — our history.

[Excerpt]

In 1904, Nature printed a speech about eugenics by the statistician Francis Galton. One of the foremost scientists of his day, Galton defined eugenics as “the science which deals with all influences that improve and develop the inborn qualities of a race”. He said that “the aim of eugenics is to represent each class or sect by its best specimens, causing them to contribute more than their proportion to the next generation”.

Galton’s scientifically inaccurate ideas about eugenics had a huge, damaging influence that the world is still grappling with. The idea that some groups — people of colour or poor people, for example — were inferior has fuelled irreparable discrimination and racism. Nature published several papers by Galton and other eugenicists, thus giving a platform to these views. At the time, eugenics “was an active area of research and considered a very legitimate one”, says Melinda Baldwin, a historian at the University of Maryland, College Park, who wrote Making Nature, a 2015 history of the journal. Nature, she says, “helped to spread eugenic doctrine by publishing those scientists”.

Galton’s papers are part of a shameful seam running through Nature’s history. Since its founding more than 150 years ago, this journal has developed a reputation for publishing some of the world’s most important scientific discoveries. But we have also published material that contributed to bias, exclusion and discrimination in research and society. Some of our articles were offensive and harmful, a legacy we are now making an overdue effort to examine and expose. They contrast starkly with the journal’s current goal of fostering equity, diversity and inclusion...

Article Open Access 11 Aug 2022

Pandemic-scale phylogenomics reveals the SARS-CoV-2 recombination landscape

A new phylogenomic method is developed that can detect recombinations in virus lineages in pandemic-scale datasets.

Yatish Turakhia, Bryan Thornlow, Russell Corbett-Detig

Nature Biotechnology

Volume 40 Issue 9, September 2022

https://www.nature.com/nbt/volumes/40/issues/9

[Reviewed earlier]
(Accessed 01 Oct 2022)
[No new digest content identified]

**Nature Genetics**
Volume 54 Issue 9, September 2022
https://www.nature.com/ng/volumes/54/issues/9
[Reviewed earlier]

**Nature Human Behaviour**
Volume 6 Issue 9, September 2022
https://www.nature.com/nathumbehav/volumes/6/issues/9
[Reviewed earlier]

**Nature Medicine**
Volume 28 Issue 9, September 2022
https://www.nature.com/nm/volumes/28/issues/9
[Reviewed earlier]

**Nature Reviews Drug Discovery**
Volume 21 Issue 9, September 2022
https://www.nature.com/nrd/volumes/21/issues/9
[Reviewed earlier]

**Nature Reviews Genetics**
Volume 23 Issue 9, September 2022
https://www.nature.com/nrg/volumes/23/issues/9
[Reviewed earlier]

**Nature Reviews Immunology**
Volume 22 Issue 9, September 2022
https://www.nature.com/nri/volumes/22/issues/9
[Reviewed earlier]

**New England Journal of Medicine**
September 29, 2022  Vol. 387 No. 13
https://www.nejm.org/toc/nejm/medical-journal
*Perspective*
**Intradermal Vaccination for Monkeypox — Benefits for Individual and Public Health**
J.T. Brooks, P. Marks, R.H. Goldstein, and R.P. Walensky
Interactive Perspective: Sickle Cell Disease and Gene Therapy — Patient and Physician Perspectives
M. DeBaun and Others
In this short documentary video from the New England Journal of Medicine, patients and physicians partner both to highlight the experience of living with sickle cell disease and to discuss the pathophysiology of the disease and new treatment strategies, including gene therapy.

Editorials
Audio Interview: Assessing Bivalent Vaccines against Covid-19
E.J. Rubin, L.R. Baden, and S. Morrissey

npj Vaccines
https://www.nature.com/npjvaccines/
[Accessed 01 Oct 2022]
Article
01 October 2022
Understanding change in COVID-19 vaccination intention with network analysis of longitudinal data from Dutch adults
Monique Chambon, Wesley G. Kammeraad, Han L. J. van der Maas

Pediatrics
Volume 150, Issue 3  September 2022
https://publications.aap.org/pediatrics/issue/150/3
[Reviewed earlier]

PharmacoEconomics
Volume 40, issue 10, October 2022
https://link.springer.com/journal/40273/volumes-and-issues/40-10
[New issue; No digest content identified]

PLoS Biology
https://journals.plos.org/plosbiology/
(Accessed 01 Oct 2022)
[No new digest content identified]

PLoS Genetics
https://journals.plos.org/plosgenetics/
(Accessed 01 Oct 2022)
[No new digest content identified]

PLoS Medicine
http://www.plosmedicine.org/
HIV prevention for the next decade: Appropriate, person-centred, prioritised, effective, combination prevention

Peter Godfrey-Faussett, Luisa Frescura, Quarraisha Abdool-Karim, Michaela Clayton, Peter D. Ghys, (on behalf of the 2025 prevention targets working group)

Abstract

- UNAIDS and a broad range of partners have collaborated to establish a new set of HIV prevention targets to be achieved by 2025 as an intermediate step towards the sustainable development target for 2030.
- The number of new HIV infections in the world continues to decline, in part due to the extraordinary expansion of effective HIV treatment. However, the decline is geographically heterogeneous, with some regions reporting a rise in incidence. The incidence target that was agreed for 2020 has been missed.
- A range of exciting new HIV prevention technologies have become available or are in the pipeline but will only have an impact if they are accessible and affordable and delivered within systems that take full account of the social and political context in which most infections occur. Most new infections occur in populations that are marginalised or discriminated against due to structural, legal, and cultural barriers.
- The new targets imply a new approach to HIV prevention that emphasises appropriate, person-centred, prioritised, effective, combination HIV prevention within a framework that reduces existing barriers to services and acknowledges heterogeneity, autonomy, and choice.
- These targets have consequences for people working in HIV programmes both for delivery and for monitoring and evaluation, for health planners setting local and national priorities, and for funders both domestic and global. Most importantly, they have consequences for people who are at risk of HIV exposure and infection.
- Achieving these targets will have a huge impact on the future of the HIV epidemic and put us back on track towards ending AIDS as a public health threat by 2030.

PLoS Neglected Tropical Diseases

http://www.plosntds.org/

[No new digest content identified]
Influenza vaccine coverage and factors associated with non-vaccination among adults at high risk for severe outcomes: An analysis of the Canadian Longitudinal Study on Aging
Katie Gravagna, Christina Wolfson, Giorgia Sulis, Sarah A. Buchan, Shelly McNeil, Melissa K. Andrew, Jacqueline McMillan, Susan Kirkland, Nicole E. Basta
Research Article | published 30 Sep 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0275135

Barriers to anti-retroviral therapy adherence among adolescents aged 10 to 19 years living with HIV in sub-Saharan Africa: A mixed-methods systematic review protocol
Londiwe D. Hlophe, Jacques L. Tamuzi, Constance Shumba, Peter S. Nyasulu
Registered Report Protocol | published 30 Sep 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0273435

To mask or not to mask: Debunking the myths of mask-wearing during COVID-19 across cultures
Rong Chen, Bih-Jen Fwu, Tong-Rong Yang, Yi-Kai Chen, Quang-Anh Ngo Tran
Research Article | published 29 Sep 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0270160

Assessing the effectiveness of COVID-19 vaccine lotteries: A cross-state synthetic control methods approach
Sam Fuller, Sara Kazemian, Carlos Algara, Daniel J. Simmons
Research Article | published 28 Sep 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0274374

COVID-19 vaccine acceptance among pregnant women worldwide: A systematic review and meta-analysis
Milad Azami, Marzieh Parizad Nasirkandy, Hadi Esmaeili Gouvarchin Ghaleh, Reza Ranjbar
Research Article | published 28 Sep 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0272273

Barriers and facilitators to vaccination for COVID-19, pertussis, and influenza during pregnancy: Protocol for an umbrella review
Bethany Nichol, Valentina Simonetti, Jemma McCready, Mary Steen, John Unsworth, Marco Tomietto
Study Protocol | published 26 Sep 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0275105

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 01 Oct 2022]

Shedding of infectious SARS-CoV-2 despite vaccination
Research Article | published 30 Sep 2022 PLOS Pathogens
https://doi.org/10.1371/journal.ppat.1010876
PNAS - Proceedings of the National Academy of Sciences of the United States
September 6, 2022 | vol. 119 | no. 36
[New issue; No digest content identified]

Prehospital & Disaster Medicine
Volume 37 - Issue 5 - October 2022
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 162  September 2022
[Reviewed earlier]

Proceedings of the Royal Society B
14 September 2022  Volume 289  Issue 1982
https://royalsocietypublishing.org/toc/rspb/current
[Reviewed earlier]

Public Health
Volume 210  Pages 1-162 (September 2022)
[Reviewed earlier]

Public Health Ethics
Volume 15, Issue 1, April 2022
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 137 Issue 4, July/August 2022
https://journals.sagepub.com/toc/phrg/137/4
[Reviewed earlier]

Qualitative Health Research
Volume 32 Issue 11, September 2022
https://journals.sagepub.com/toc/qhra/current
[Reviewed earlier]
Research Ethics
Volume 18 Issue 4, October 2022
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 01 Oct 2022]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
30 Sep 2022
Adverse reactions to drugs used for COVID-19 in five Latin American countries
Original research | Spanish |

27 Sep 2022
Social determinants associated with self-reporting of symptoms and access to COVID-19 testing and diagnosis in the Plurinational State of Bolivia
Original research | Spanish |

Risk Analysis
Volume 42, Issue 8 Pages: 1603-1890 August 2022
https://onlinelibrary.wiley.com/toc/15396924/current
Special Issue: Machine Learning and Other Information Analyses for Risk in Social Networks
[Reviewed earlier]

Risk Management and Healthcare Policy
[Accessed 01 Oct 2022]
Original Research
Myth and Misinformation on COVID-19 Vaccine: The Possible Impact on Vaccination Refusal Among People of Northeast Ethiopia: A Community-Based Research
Kalayou MH, Awol SM
Published Date: 1 October 2022

Science
Volume 377| Issue 6614| 30 Sep 2022
**Policy Forum**

**A framework for sex, gender, and diversity analysis in research**
BY Lilian Hunt, Mathias Wullum Nielsen, Londa Schiebinger
29 Sep 2022: 1492-1495

Funding agencies have ample room to improve their policies.

**Reviews**

**Understanding pathogen survival and transmission by arthropod vectors to prevent human disease**
BY Carolina Barillas-Mury, José M. C. Ribeiro, Jesus G. Valenzuela
30 Sep 2022

A review discusses how molecular and genetic tools provide insights into the biology of disease transmission by arthropod vectors.

**Science and Engineering Ethics**
Volume 28, issue 5, October 2022

**Stakeholders’ Experiences of Research Integrity Support in Universities: A Qualitative Study in Three European Countries**
Authors (first, second and last of 8)
Natalie Evans
Ivan Buljan
the EnTIRE consortium
Content type: Original Research/Scholarship
Open Access
Published: 30 August 2022
Article: 43

**Towards a Design Toolkit of Informed Consent Models Across Fields: A Systematic Review**
Authors
Iris Loosman
Philip J. Nickel
Content type: Original Research/Scholarship
Open Access
Published: 30 August 2022
Article: 42

**Science Translational Medicine**
Volume 14| Issue 664| 28 Sep 2022
https://www.science.org/toc/stm/current
[New issue; No digest content identified]

**Social Science & Medicine**
Volume 307  August 2022
Identifying performance factors of long-term care facilities in the context of the COVID-19 pandemic: a scoping review protocol

Long-term care facilities (LTCFs) have been severely affected by the COVID-19 pandemic with serious consequences for the residents. Some LTCFs performed better than others, experiencing lower case and death ra...

Authors: Josiane Létourneau, Emilie Bélanger, Drissa Sia, Idrissa Beogo, Stephanie Robins, Katya Kruglova, Maripier Jubinville and Eric Nguemeleu Tchouaket

Citation: Systematic Reviews 2022 11:203
Content type: Protocol Published on: 23 September 2022
Advanced vaccinology training globally: Update and impact of the COVID-19 crisis
Carine Dochez, Philippe Duclos, Noni MacDonald, Christoph Steffen, ... Paul-Henri Lambert
Pages 5683-5690

Vaccine financing in the Middle East and Africa: An overview from 2010 to 2019
Janetta Catharina de Beer, Daisuke Goto, Helen Miller-Janson, Ryan Holl, Goran Bencina
Pages 5691-5700

Abstract
Background
Vaccination is a cost-effective disease prevention measure. Sustainable financing is critical to successful implementation of vaccination programs. Countries in the Middle East and Africa (MEA) have vaccination programs that remain highly vulnerable to budget limitations.
Objectives
The objectives of this study were to understand the current vaccine financing landscape in MEA; to assess the availability and variability of data on vaccination budgets, expenditure and schedules including introductions of new vaccines; and to identify and describe key trends.
Method
A targeted literature review was conducted for 69 MEA countries for data between 2010 and 2019. Descriptive analysis of the collected data was conducted.
Results
Data on vaccination expenditure were available for 96% of the countries. However, data on vaccination budget were limited, and the variability was high. The median vaccination expenditure per capita was between US$0.57 and US$1.02. High-income countries spent the most on vaccination per capita (median US$3.41) compared to low-income countries (median US$0.69). The highest vaccination expenditure per capita was in countries that receive 100% government funding of vaccination programs (US$0.87) compared to those where government pays for > 0% to < 50% of vaccination expenditure (US$0.74). Vaccination expenditure as a proportion of gross domestic product was the highest (0.10%) in low-income countries and the lowest in high-income countries (0.01%). Vaccination expenditure as proportion of healthcare expenditure was the highest (1.76%) in low-income countries and the lowest in high-income countries (0.33%). Statistically significant trends in median expenditure per capita were identified for 27% of the countries. During this period, an average of 4.4 vaccines were introduced.
Conclusion
Data on vaccination expenditure in MEA was available for detailed analysis, and it was useful to understand the characteristics of vaccination funding in the region. It is important to secure adequate financing to sustain current vaccination programs and to introduce new vaccines.
Vaccination is the main tool available to handle the COVID-19 pandemic globally. Though no vaccine is proven to be 100% effective, vaccination secures against getting seriously ill and dying from the disease. Russia announced the development of its first domestic vaccine back in August 2020 and launched the nationwide immunization campaign at the beginning of 2021. Despite these achievements, as of mid-October 2021, only 36% of the population got at least one shot of the vaccine. Massive vaccination hesitancy and refusal pose a great threat to public health and postpone social and economic recovery. Using nationally representative data from the general adult population of Russia, this study explores the scope of vaccination hesitancy and refusal as well as the determinants of vaccination attitudes. The results suggest that only 45% of the Russian population demonstrated positive attitudes towards the COVID-19 vaccination prior to the launch of a nationwide vaccination program. We analyze a wide array of demographic, socio-economic, and health-related factors in relation to vaccination intentions and explore the deep-rooted causes of vaccination reluctance by looking at personality traits, religiosity, and trust. The obtained results are vital for designing policy measures to promote vaccination.

Value in Health
September 2022 Volume 25 Issue 9 p1463-1662
https://www.valueinhealthjournal.com/current
[Reviewed earlier]

:::::::
:::::::

Pre-Print Servers

Gates Open Research
https://gatesopenresearch.org/browse/articles
Selected Research
Research Article metrics
Revised

Modeling anticipated changes in numbers of SARS-CoV-2 infections within communities due to immunization campaigns [version 2; peer review: 2 approved with reservations]
Kurt Frey, Brittany Hagedorn, Kevin A. McCarthy, Raymond Hutubessy, Susan Annemarie Wang
Peer Reviewers Sabina Marchetti; Sylvia K. Ofori
Funder
Global Good Fund
LATEST VERSION PUBLISHED 27 Sep 2022

Abstract
Background: As SARS-CoV-2 spread in early 2020, uncertainty about the scope, duration, and impact of the unfolding outbreaks caused numerous countries to interrupt many routine activities, including health services. Because immunization is an essential health service, modeling changes in SARS-CoV-2 infections among communities and health workers due to different vaccination activities was undertaken to understand the risks and to inform approaches to resume services.
Methods: Agent-based modeling examined the impact of Supplemental Immunization Activities (SIAs) delivery strategies on SARS-CoV-2 transmission in communities and health workers for six countries capturing various demographic profiles and health system performance: Angola, Ecuador, Lao PDR, Nepal, Pakistan, and Ukraine.
Results: Urban, fixed-post SIAs during periods of high SARS-CoV-2 prevalence increased infections within the community by around 28 [range:0-79] per 1000 vaccinations. House-to-house SIAs in mixed urban and rural contexts may import infections into previously naïve communities. Infections are elevated by around 60 [range:0-230] per 1000 vaccinations, but outcomes are sensitive to prevalence in health workers and SIA timing relative to peak.

Conclusions: Incremental increases in SARS-CoV-2 infection due to SIAs was small and in proportion to overall prevalence. Younger populations experience lower transmission intensity and fewer excess infections per childhood vaccine delivered. Large rural populations have lower transmission intensity but face a greater risk of introduction of SARS-CoV-2 during an SIA.

medRxiv
https://www.medrxiv.org/content/about-medrxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

Selected Research
When Case Reporting Becomes Untenable: Can Sewer Networks Tell Us Where COVID-19 Transmission Occurs?
Yuke Wang, Pengbo Liu, Jamie VanTassell, Stephen P. Hilton, Lizheng Guo, Orlando Sablon, Marlene K Wolfe, Lorenzo Freeman, Wayne Rose, Carl Holt, Mikita Browning, Michael Bryan, Lance A. Waller, Peter F.M. Teunis, Christine L. Moe
medRxiv 2022.09.29.22280508; doi: https://doi.org/10.1101/2022.09.29.22280508

Global patterns and correlates in the emergence of antimicrobial resistance in humans
Emma Mendelsohn, Noam Ross, Carlos Zambrana-Torrelio, Thomas Van Boeckel, Ramanan Laxminarayan, Peter Daszak
medRxiv 2022.09.29.22280519; doi: https://doi.org/10.1101/2022.09.29.22280519

Vaccine Approach for Human Monkeypox over the Years and Current Recommendations to Prevent the Outbreak: A Rapid Review
Rifat Ara, Tajrin Rahman, Rima Nath, A.M.Khairul islam, Miah MD Akiful Haque, Md. Ferdous Rahman, Mohammad Delwer Hossain Hawlader
medRxiv 2022.09.29.22280481; doi: https://doi.org/10.1101/2022.09.29.22280481

Impact of Differential Vaccine Effectiveness on COVID-19 Hospitalization Cases: Projections for 10 Developed Countries where Booster Vaccines were Recommended
Michael Maschio, Kelly Fust, Amy Lee, Nicolas Van de Velde, Philip O. Buck, Michele A. Kohli

The role of perceived expertise and trustworthiness in research study and clinical trial recruitment: Perspectives of clinical research coordinators and African American and Black Caribbean patients
Susan E. Morgan, Tyler R. Harrison, Kallia O. Wright, Xiaofeng Jia, Bonnie Deal, Kate Malova
Evaluation of health system resilience in 60 countries based on their responses to COVID-19
Laijun Zhao, Yajun Jin, Lixin Zhou, Pingle Yang, Ying Qian, Xiaoyan Huang, Mengmeng Min
medRxiv 2022.09.25.22280337; doi: https://doi.org/10.1101/2022.09.25.22280337

We developed a resilience evaluation system for national health systems based on their responses to COVID-19 using four resilience dimensions: government governance and prevention, health financing, health service provision, and health workers. We determined the weight of each index by combining the three-scale and entropy-weight methods. Then, based on data from 2020, we used the Technique for Order of Preference by Similarity to Ideal Solution (TOPSIS) method to rank the health system resilience of 60 countries, then used hierarchical clustering to classify countries into groups based on their resilience level. Finally, we analyzed the causes of differences among countries in their resilience based on the four resilience dimensions...

Switzerland, Japan, Germany, Australia, South Korea, Canada, New Zealand, Finland, the United States, and the United Kingdom had the highest health system resilience in 2020. Eritrea, Nigeria, Libya, Tanzania, Burundi, Mozambique, Republic of the Niger, Benin, Côte d’Ivoire, and Guinea had the lowest resilience. Government governance and prevention of COVID-19 will greatly affect a country’s success in fighting future epidemics, which will depend on a government’s emergency preparedness, stringency (a measure of the number and rigor of the measures taken), and testing capability. Given the lack of vaccines or specific drug treatments during the early stages of the 2020 epidemic, social distancing and wearing masks were the main defenses against COVID-19. Cuts in health financing had direct and difficult to reverse effects on health systems. In terms of health service provision, the number of hospitals and intensive care unit beds played a key role in COVID-19 clinical care...

The impact of COVID-19 vaccination in the US: averted burden of SARS-COV-2-related cases, hospitalizations and deaths
Teresa K. Yamana, Marta Galanti, Sen Pei, Manuela Di Fusco, Frederick J. Angulo, Mary M. Moran, Farid Khan, David L. Swerdlow, Jeffrey Shaman
medRxiv 2022.09.23.22280281; doi: https://doi.org/10.1101/2022.09.23.22280281

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences
[Accessed 01 Oct 2022]

Sharp reductions in COVID-19 case fatalities and excess deaths in Peru in close time conjunction, state-by-state, with ivermectin treatments
Juan Chamie-Quintero
Jennifer Hibberd
David Scheim
Last edited: Sep 27, 2022 UTC

Medicine and Health Sciences Diseases Virus Diseases
On May 8, 2020, Peru’s Ministry of Health approved ivermectin (IVM) for the treatment of COVID-19. A drug of Nobel Prize-honored distinction, IVM has been safely distributed in 3.7 billion doses worldwide since 1987

Wellcome Open Research [to 01 Oct 2022]
https://wellcomeopenresearch.org/browse/articles
Selected Research

Research Article

Revised

Effectiveness of seasonal malaria chemoprevention administered in a mass campaign in the Kedougou region of Senegal in 2016: a case-control study [version 2; peer review: 1 approved with reservations]

Isaac Akhenaton Manga, Fassiatou Tairou, Amadou Seck, Ekoue Kouevidjin, Khadime Sylla, Doudou Sow, Alioune Babara Gueye, Mady Ba, Magatte Ndiaye, Roger Clément Kouly Tine, Omar Gaye, Babacar Faye, Jean Louis Abdourahim Ndiaye

Peer Reviewer Drissa Konaté

Funders

Wellcome

Republic of Senegal (Ministry of Health/National Malaria Control Program)

LATEST VERSION PUBLISHED 30 Sep 2022

Research Article

Revised

Putting youth at the centre: co-design of a community-based intervention to improve HIV outcomes among youth in Zimbabwe [version 2; peer review: 1 approved with reservations]

Constance Mackworth-Young, Stefanie Dringus, Ethel Dauya, Chido Dziva Chikwari, Constancia Mavodza, Mandikudza Tembo, Aoife Doyle, Grace McHugh, Victoria Simms, Maurice Wedner-Ross, Tsitsi Apollo, Owen Mugurungi, Rashida Ferrand, Sarah Bernays

Peer Reviewer Christina A. Laurenzi

Funder

Wellcome Trust

LATEST VERSION PUBLISHED 30 Sep 2022

Open Letter

AWAITING PEER REVIEW

Maximising impactful and locally relevant mental health research: ethical considerations [version 1; peer review: awaiting peer review]

Clara Calia, Amit Chakrabarti, Emmanuel Sarabwe, Anna Chiumento

Peer Reviewers Invited

Funders

Global Forum on Bioethics in Research

Medical Research Council

Indian Council of Medical Research

SFC-GCRF Covid-19 urgent call

PUBLISHED 26 Sep 2022

* * * * *

Think Tanks

Brookings [to 01 Oct 2022]

http://www.brookings.edu/

Latest Research [Selected]
Center for Global Development  [to 01 Oct 2022]
https://www.cgdev.org/
All Research [Selected]
No new digest content identified

Chatham House  [to 01 Oct 2022]
https://www.chathamhouse.org/
Selected Analysis, Comment
No new digest content identified

CSIS  [to 01 Oct 2022]
https://www.csis.org/
Selected Reports
Report
Gender Equity to Improve Immunization Services
September 29, 2022 | Katherine E. Bliss
The Issue
The Covid-19 pandemic has underscored the importance of a strong health workforce to outbreak response, as well as of vaccine delivery to prevent further outbreaks. Women and men providing care, transporting supplies, analyzing data, and delivering vaccines to patients and their families have all contributed to pandemic-related activities while maintaining a focus on routine health programs. Women comprise an estimated two-thirds of the formal health workforce worldwide—and a high percentage of the unpaid health workforce as well. Yet gender inequities, including those related to training, compensation, and professional advancement, limit opportunities for female health workers to perform their duties and develop professionally, with implications for quality of care and health outcomes. By prioritizing gender equity within their own health workforces; gathering data on gender dynamics within the immunization programs they support; and supporting initiatives to train, retain, and advance the careers of female immunization workers, donor governments—including the United States, working with bilateral and multilateral partners—can strengthen quality of care, improve global immunization coverage, and reinforce health security in the long run.

Kaiser Family Foundation  [to 01 Oct 2022]
https://www.kff.org/search/?post_type=press-release
Press Releases
September 30, 2022  News Release
Half of Public Has Heard Little or Nothing About the New COVID-19 Booster Aimed at Omicron; Many Don’t Know If the CDC Recommends That They Get the New Booster
Nearly 1 in 5 Parents of Children Under 5 Say Their Child Has Gotten a Vaccine, up from 7% in July, Though Half Say They Will “Definitely Not” Get Their Child Vaccinated

ODI  [Overseas Development Institute]  [to 01 Oct 2022]
The Sustainable Development Goal of universal health coverage, coupled with the withdrawal of international donors in a growing number of countries, has underscored the need for resource prioritisation in the health sector in low- and middle-income countries. These shifts pose not only a financing challenge but also an institutional one. In this paper, profiles of Laos, Liberia and Kenya illustrate the different challenges countries were facing in 2019 and the complex institutional landscapes involved in health financing decisions. We identify three key domains where more targeted attention could be directed when developing donor transition strategies, when strengthening national decision-making processes, and in future research. These are the interfaces between (1) domestic and international financing, (2) national planning and budgeting, and (3) central and subnational levels of government.

**Pew Research Center** [to 01 Oct 2022]
https://www.pewresearch.org/
*Latest Publications [Selected]*
*Short Read / Sep 27, 2022*

**About half of recent online daters in U.S. say it’s important to see COVID-19 vaccination status on profiles**

Online dating users who are Democrats are far more likely their Republican counterparts to say someone’s vaccination status is important for them to see.

**Rand** [to 01 Oct 2022]
https://www.rand.org/pubs.html
*Reports, Selected Journal Articles*
*No new digest content identified.*

**Urban Institute** [to 01 Oct 2022]
https://www.urban.org/publications

*New Research Publications*

**Research Report**

**Decennial Disclosure: An Explainer on Formal Privacy and the TopDown Algorithm**

September 29, 2022

Although collecting more and better data can provide great benefits to society, such as furthering medical research or targeting investments to those most in need, data privacy concerns surface from those charged with protecting data when that information can be de-anonymized and used maliciously.

For example, the US Census Bureau conducted a simulated attack on the 2010 Decennial Census and discovered they could reidentify about one-sixth of the US population using publicly available data (such as name, sex, and age) from external sources, like public social media profiles (Leclerc 2019). This type of attack on the 2020 Decennial Census has the potential to be even more disclosive because...
of the detailed information collected, such as more race and ethnicity categories, that could lead to more individuals being identified with great specificity...

*Brief*

Conducting Research with the Deaf Community
September 29, 2022

*Research Report*

Do No Harm Guide: Additional Perspectives on Data Equity
September 28, 2022

...For this follow-up volume, Do No Harm Guide: Additional Perspectives on Data Equity, we handed the pen to data experts and practitioners whose voices have been traditionally underrepresented. As with the original guide, the lessons within this accompanying volume are not meant to be prescriptive—rather, they should inspire greater thoughtfulness and consideration in data work..

World Economic Forum  [to 01 Oct 2022]
https://www.weforum.org/press/

Media
No new digest content identified.

* * * * *

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health,
human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.